Abstract
The progressive production and subsequent accumulation of β-amyloid (Aβ), a proteolytic fragment of the membrane-associated amyloid precursor protein (APP), plays a central role in Alzheimers Disease (AD). Aβ is released in a soluble form that may be responsible for cognitive dysfunction in the early stages of the disease, then progressively forms oligomeric, multimeric and fibrillar aggregates, triggering neurodegeneration. Eventually, the aggregation and accumulation of Aβ culminates with the formation of extracellular plaques, one of the morphological hallmarks of the disease, detectable post-mortem in AD brains. In this review we report the known structural features of amyloid peptides and fibrils, and we give an overview of all small molecules that have been found to interact with Aβ aggregation. Deeper knowledge of the mechanism leading to amyloid fibrils along with their molecular structure and the molecular interactions responsible for activity of small molecules could supply useful information for the design of new AD therapeutic agents.
Keywords: β-amyloid, Alzheimer's disease, aggregation inhibitors
Current Medicinal Chemistry
Title: Beta Amyloid Aggregation Inhibitors: Small Molecules as Candidate Drugs for Therapy of Alzheimers Disease
Volume: 17 Issue: 27
Author(s): F. Re, C. Airoldi, C. Zona, M. Masserini, B. La Ferla, N. Quattrocchi and F. Nicotra
Affiliation:
Keywords: β-amyloid, Alzheimer's disease, aggregation inhibitors
Abstract: The progressive production and subsequent accumulation of β-amyloid (Aβ), a proteolytic fragment of the membrane-associated amyloid precursor protein (APP), plays a central role in Alzheimers Disease (AD). Aβ is released in a soluble form that may be responsible for cognitive dysfunction in the early stages of the disease, then progressively forms oligomeric, multimeric and fibrillar aggregates, triggering neurodegeneration. Eventually, the aggregation and accumulation of Aβ culminates with the formation of extracellular plaques, one of the morphological hallmarks of the disease, detectable post-mortem in AD brains. In this review we report the known structural features of amyloid peptides and fibrils, and we give an overview of all small molecules that have been found to interact with Aβ aggregation. Deeper knowledge of the mechanism leading to amyloid fibrils along with their molecular structure and the molecular interactions responsible for activity of small molecules could supply useful information for the design of new AD therapeutic agents.
Export Options
About this article
Cite this article as:
Re F., Airoldi C., Zona C., Masserini M., Ferla B. La, Quattrocchi N. and Nicotra F., Beta Amyloid Aggregation Inhibitors: Small Molecules as Candidate Drugs for Therapy of Alzheimers Disease, Current Medicinal Chemistry 2010; 17 (27) . https://dx.doi.org/10.2174/092986710791959729
DOI https://dx.doi.org/10.2174/092986710791959729 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Progress in Target Drug Molecules for Alzheimer's Disease
Current Topics in Medicinal Chemistry Health Economic Modelling in Stratified Medicine - Example Depression
Current Pharmacogenomics and Personalized Medicine Intravenous Immunoglobulin Therapy in Dermatologic Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Recent Advances on α-Synuclein Cell Biology: Functions and Dysfunctions
Current Molecular Medicine Canonical and Non-Canonical Barriers Facing AntimiR Cancer Therapeutics
Current Medicinal Chemistry Caveolin-1 in Stroke Neuropathology and Neuroprotection: A Novel Molecular Therapeutic Target for Ischemic-Related Injury
Current Vascular Pharmacology The 21st Century Form of Vitamin E - Tocotrienol
Current Pharmaceutical Design Novel Targets in Multiple Sclerosis: To Oxidative Stress and Beyond
Current Topics in Medicinal Chemistry From Small to Big Molecules: How Do We Prevent and Delay the Progression of Age-Related Neurodegeneration?
Current Pharmaceutical Design Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?
Current Pharmaceutical Design Physcion and Physcion 8-O-β-D-glucopyranoside: Natural Anthraquinones with Potential Anticancer Activities
Current Drug Targets Implications of Vitamin D in Multiple Sclerosis and Other Neurodegenerative Processes: Bibliometric Analysis and Systematic Review
CNS & Neurological Disorders - Drug Targets Elevated Aβ42 in Aged, Non-demented Individuals with Cerebral Atherosclerosis
Current Alzheimer Research Cholinergic Targets in Lung Cancer
Current Pharmaceutical Design Amyloid-Related Biomarkers for Alzheimers Disease
Current Medicinal Chemistry A Series of New Hydrazone Derivatives: Synthesis, Molecular Docking and Anticholinesterase Activity Studies
Mini-Reviews in Medicinal Chemistry Disorders of Respiration and Sleep-Disordered Breathing in Patients with Chronic Renal Failure
Current Respiratory Medicine Reviews The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders
Current Pharmaceutical Design Targeting the Immune System in Cancer
Current Pharmaceutical Biotechnology Current and Promising Pharmacotherapies, and Novel Research Target Areas in the Treatment of Alcohol Dependence: A Review
Current Pharmaceutical Design